Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with ...

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the May 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options ...

If an investor was to purchase shares of BIIB stock at the current price level of $261.97/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...

May 05, 2025 — 10:20 am EDT Written by Quiver ForecastTracker for Quiver Quantitative -> ...

Our analysis of options history for Biogen (NASDAQ: BIIB) revealed 12 unusual trades. Delving into the details, we found 25% of traders were bullish, while 66% showed bearish tendencies.

We regret to report that long term Biogen Inc. (NASDAQ:BIIB) shareholders have had that experience, with the share price dropping 20% in three years, versus a market return of about 89%.

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the July 29th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options ...

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the April 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the June 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Biogen Inc (Symbol: BIIB), where a total of 11,859 contracts have traded so far ...

At $310.58, the average BIIB stock price target of $310.58 suggests a modest upside potential of 1.8% from current levels. Biogen stock has rallied over 27% so far this year. IQVIA Holdings (IQV ...

In recent trading, shares of Biogen Inc (Symbol: BIIB) have crossed above the average analyst 12-month target price of $247.28, changing hands for $276.61/share. When a stock reaches the target an ...